About Dicerna Pharmaceuticals (NASDAQ:DRNA)
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company's preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097
Debt
Debt-to-Equity RatioN/A
Current Ratio7.12%
Quick Ratio7.12%
Price-To-Earnings
Trailing P/E Ratio-2.78
Forward P/E Ratio-10.50
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.28 million
Price / Sales274.29
Cash FlowN/A
Price / CashN/A
Book Value$1.96 per share
Price / Book6.16
Profitability
EPS (Most Recent Fiscal Year)($3.66)
Net Income$-60,040,000.00
Net Margins-2,637.15%
Return on Equity-171.81%
Return on Assets-71.11%
Miscellaneous
Employees44
Outstanding Shares51,770,000
Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions
What is Dicerna Pharmaceuticals' stock symbol?
Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."
How were Dicerna Pharmaceuticals' earnings last quarter?
Dicerna Pharmaceuticals (NASDAQ:DRNA) issued its quarterly earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.65) by $0.25. The biopharmaceutical company earned $1.40 million during the quarter, compared to the consensus estimate of $1.45 million. Dicerna Pharmaceuticals had a negative return on equity of 171.81% and a negative net margin of 2,637.15%. The firm's quarterly revenue was up 976.9% on a year-over-year basis. View Dicerna Pharmaceuticals' Earnings History.
When is Dicerna Pharmaceuticals' next earnings date?
What price target have analysts set for DRNA?
7 equities research analysts have issued 12 month price objectives for Dicerna Pharmaceuticals' stock. Their forecasts range from $10.00 to $17.00. On average, they anticipate Dicerna Pharmaceuticals' stock price to reach $13.20 in the next twelve months. View Analyst Ratings for Dicerna Pharmaceuticals.
What are Wall Street analysts saying about Dicerna Pharmaceuticals stock?
Here are some recent quotes from research analysts about Dicerna Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. " (2/9/2018)
- 2. Cowen Inc analysts commented, "DRNA reported 1Q17 results today." (5/9/2017)
Who are some of Dicerna Pharmaceuticals' key competitors?
Some companies that are related to Dicerna Pharmaceuticals include TG Therapeutics (TGTX), CytomX Therapeutics (CTMX), Retrophin (RTRX), Zai Lab (ZLAB), MacroGenics (MGNX), Uniqure (QURE), Biohaven Pharmaceutical (BHVN), Flexion Therapeutics (FLXN), Alder BioPharmaceuticals (ALDR), Assembly Biosciences (ASMB), Access Pharmaceuticals (ABEO), Amarin (AMRN), Amphastar Pharmaceuticals (AMPH), Mirati Therapeutics (MRTX), Lexicon Pharmaceuticals (LXRX), Inflarx (IFRX), Eagle Pharmaceuticals (EGRX) and Collegium Pharmaceutical (COLL).
Who are Dicerna Pharmaceuticals' key executives?
Dicerna Pharmaceuticals' management team includes the folowing people:
- Dr. Douglas M. Fambrough III, Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 49)
- Mr. John B. Green CPA, Chief Financial Officer (Age 64)
- Dr. Bob D. Brown Ph.D., Chief Scientific Officer and Sr. VP (Age 53)
- Dr. Mark Behlke M.D., Ph.D., Co-Founder and Member of Scientific Advisory Board
- Prof. John J. Rossi Ph.D., Co-Founder and Chairman of Scientific Advisory Board (Age 71)
Has Dicerna Pharmaceuticals been receiving favorable news coverage?
News articles about DRNA stock have trended somewhat positive on Friday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 0.04 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Dicerna Pharmaceuticals?
Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dicerna Pharmaceuticals' stock price today?
One share of DRNA stock can currently be purchased for approximately $12.00.
How big of a company is Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals has a market capitalization of $543.04 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.
How can I contact Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]
MarketBeat Community Rating for Dicerna Pharmaceuticals (DRNA)
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Dicerna Pharmaceuticals (NASDAQ:DRNA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Dicerna Pharmaceuticals in the last 12 months. Their average twelve-month price target is $13.20, suggesting that the stock has a possible upside of 9.27%. The high price target for DRNA is $17.00 and the low price target for DRNA is $10.00. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.57 | 2.86 | 2.67 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $13.20 | $12.20 | $8.75 | $5.3333 |
| Price Target Upside: | 9.27% upside | 9.63% downside | 0.91% downside | 63.60% upside |
Dicerna Pharmaceuticals (NASDAQ:DRNA) Consensus Price Target History
Dicerna Pharmaceuticals (NASDAQ:DRNA) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Dicerna Pharmaceuticals (NASDAQ:DRNA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Dicerna Pharmaceuticals (NASDAQ DRNA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 29.41%
Institutional Ownership Percentage: 75.28%
Dicerna Pharmaceuticals (NASDAQ DRNA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/19/2018 | James B Weissman | Insider | Sell | 1,035 | $13.00 | $13,455.00 | 18,765 |  |
| 12/18/2017 | Bain Capital Life Sciences Inv | Director | Buy | 285,000 | $7.00 | $1,995,000.00 | | |
| 11/16/2016 | Dennis Langer | Director | Sell | 23,766 | $3.52 | $83,656.32 | 43,595 | |
| 11/15/2016 | Douglas Fambrough | CEO | Buy | 33,100 | $3.71 | $122,801.00 | | |
| 5/12/2016 | James B Weissman | Insider | Buy | 5,000 | $3.29 | $16,450.00 | 15,100 | |
| 11/25/2014 | James E Flynn | Insider | Sell | 321,965 | $11.36 | $3,657,522.40 | | |
| 11/7/2014 | James E Flynn | Insider | Sell | 214,164 | $9.05 | $1,938,184.20 | | |
| 10/15/2014 | James E Flynn | Insider | Sell | 117,778 | $10.86 | $1,279,069.08 | | |
| 10/14/2014 | James E Flynn | Major Shareholder | Sell | 36,115 | $11.02 | $397,987.30 | | |
| 10/10/2014 | James E Flynn | Major Shareholder | Sell | 30,214 | $12.13 | $366,495.82 | | |
| 2/4/2014 | James E Flynn | Insider | Buy | 1,000,000 | $15.00 | $15,000,000.00 | | |
| 2/4/2014 | Stephen J Hoffman | Director | Buy | 200,000 | $15.00 | $3,000,000.00 | | |
(Data available from 1/1/2013 forward)
Dicerna Pharmaceuticals (NASDAQ DRNA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Dicerna Pharmaceuticals (DRNA) Expected to Post Quarterly Sales of $1.75 Million
www.americanbankingnews.com - April 18 at 4:15 AM |
| Zacks: Brokerages Expect Dicerna Pharmaceuticals (DRNA) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 16 at 9:25 AM |
| ValuEngine Lowers Dicerna Pharmaceuticals (DRNA) to Sell
www.americanbankingnews.com - April 14 at 2:31 PM |
| Dicerna Pharmaceuticals (DRNA) Raised to "Buy" at ValuEngine
www.americanbankingnews.com - April 12 at 11:18 AM |
 | Dicerna Pharmaceuticals (DRNA) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 5:03 PM |
 | Dicerna to Present at the HC Wainwright Global Life Sciences Conference
www.businesswire.com - April 3 at 8:56 AM |
 | Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 3 at 8:56 AM |
| Dicerna Pharmaceuticals (DRNA) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 1 at 10:20 PM |
| Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Quarterly Sales of $1.75 Million
www.americanbankingnews.com - April 1 at 4:04 AM |
| Dicerna Pharmaceuticals (DRNA) Lifted to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM |
| Dicerna Pharmaceuticals (DRNA) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 9:27 AM |
| Equities Analysts Issue Forecasts for Dicerna Pharmaceuticals Inc's FY2018 Earnings (DRNA)
www.americanbankingnews.com - March 30 at 7:05 AM |
| Dicerna Pharmaceuticals Inc (DRNA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 28 at 5:56 PM |
| Dicerna Pharmaceuticals (DRNA) Coverage Initiated by Analysts at Evercore ISI
www.americanbankingnews.com - March 28 at 2:06 PM |
| Dicerna Pharmaceuticals (DRNA) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - March 28 at 11:26 AM |
| B. Riley Initiates Coverage on Dicerna Pharmaceuticals (DRNA)
www.americanbankingnews.com - March 28 at 8:06 AM |
| Dicerna Pharmaceuticals (DRNA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM |
| Dicerna Pharmaceuticals (DRNA) Lifted to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 24 at 8:23 PM |
 | H.C. Wainwright Downgrades Dicerna Pharmaceuticals (DRNA) to Neutral Citing Valuation
www.streetinsider.com - March 24 at 4:55 PM |
| Dicerna Pharmaceuticals (DRNA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 23 at 11:22 PM |
| HC Wainwright Lowers Dicerna Pharmaceuticals (DRNA) to Neutral
www.americanbankingnews.com - March 23 at 2:56 PM |
| Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - March 23 at 8:49 AM |
 | 21 Stocks Moving In Thursday's Pre-Market Session - Benzinga
www.benzinga.com - March 22 at 9:01 AM |
| Dicerna Pharmaceuticals Inc (DRNA) Insider James B. Weissman Sells 1,035 Shares
www.americanbankingnews.com - March 21 at 10:10 PM |
| Dicerna Pharmaceuticals Inc (DRNA) Expected to Announce Quarterly Sales of $1.79 Million
www.americanbankingnews.com - March 15 at 1:39 PM |
| Dicerna Pharmaceuticals (DRNA) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
seekingalpha.com - March 13 at 6:54 PM |
| Dicerna Pharmaceuticals (DRNA) Price Target Increased to $17.00 by Analysts at Stifel Nicolaus
www.americanbankingnews.com - March 9 at 8:42 PM |
| Dicerna Pharmaceuticals (DRNA) Receives New Coverage from Analysts at Chardan Capital
www.americanbankingnews.com - March 9 at 9:18 AM |
| Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium - Business Wire (press release)
www.businesswire.com - March 9 at 9:04 AM |
| Dicerna Pharmaceuticals' (DRNA) CEO Douglas Fambrough on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 9:04 AM |
| Dicerna Pharmaceuticals (DRNA) Releases Quarterly Earnings Results, Misses Expectations By $0.25 EPS
www.americanbankingnews.com - March 8 at 9:13 PM |
| Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate Update
finance.yahoo.com - March 8 at 6:06 PM |
| Dicerna to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 8:47 AM |
| Dicerna Pharmaceuticals Inc (DRNA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 3 at 5:56 PM |
| Dicerna Pharmaceuticals (DRNA) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 2 at 8:10 PM |
| Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018
finance.yahoo.com - March 1 at 8:39 AM |
| Zacks: Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Quarterly Sales of $4.43 Million
www.americanbankingnews.com - February 26 at 10:48 AM |
| Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) to Post -$0.56 EPS
www.americanbankingnews.com - February 24 at 9:26 AM |
| BidaskClub Upgrades Dicerna Pharmaceuticals (DRNA) to Buy
www.americanbankingnews.com - February 21 at 10:34 PM |
 | VYGR Soars On Alzheimer's Deal, RARX Up 21% In 5 Days, ATXI Catches Eyes
www.nasdaq.com - February 21 at 8:49 AM |
| Dicerna Pharmaceuticals Inc (DRNA) Short Interest Update
www.americanbankingnews.com - February 11 at 1:52 AM |
| Dicerna Pharmaceuticals (DRNA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 9 at 10:04 PM |
| Zacks: Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Announce Quarterly Sales of $4.43 Million
www.americanbankingnews.com - February 9 at 4:12 AM |
| Analysts Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Earnings of -$0.61 Per Share
www.americanbankingnews.com - February 7 at 9:52 AM |
| Brokers Issue Forecasts for Dicerna Pharmaceuticals Inc's FY2017 Earnings (DRNA)
www.americanbankingnews.com - February 7 at 9:22 AM |
| Dicerna Pharmaceuticals Inc (DRNA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 6 at 5:42 PM |
| SunTrust Banks Begins Coverage on Dicerna Pharmaceuticals (DRNA)
www.americanbankingnews.com - February 5 at 8:42 PM |
| Dicerna Pharmaceuticals (DRNA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 1 at 9:48 PM |
| BidaskClub Lowers Dicerna Pharmaceuticals (DRNA) to Hold
www.americanbankingnews.com - January 31 at 11:58 PM |
| Dicerna Pharmaceuticals (DRNA) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - January 28 at 9:30 AM |
Dicerna Pharmaceuticals (NASDAQ:DRNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Dicerna Pharmaceuticals (NASDAQ:DRNA) Income Statement, Balance Sheet and Cash Flow Statement
Dicerna Pharmaceuticals (NASDAQ DRNA) Stock Chart for Friday, April, 20, 2018
Loading chart…
